SUBSCRIBE
SUBSCRIBE

Juvena Therapeutics

NEWS
Map of NextGen Class of 2024/BioSpace
Business
NextGen Class of 2024: Top Life Sciences Startups to Watch This Year
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
January 3, 2024
 · 
20 min read
 · 
BioSpace Editorial Staff
Dr. Jeremy O'Connell and Dr. Hanadie Yousef, Cofou
Drug Development
Juvena Nets $41M to Demystify the Therapeutic Potential of Secreted Proteins
Juvena Therapeutics pulled in $41 million in Series A financing to advance research into the therapeutic potential of secreted proteins to target chronic and age-related diseases.
November 8, 2022
 · 
3 min read
 · 
Rosemary Scott
IN THE PRESS
FDA
Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1
January 23, 2024
 · 
4 min read
Business
Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development
January 25, 2023
 · 
3 min read
Biotech Bay
Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases
November 8, 2022
 · 
5 min read
Biotech Bay
Juvena Therapeutics Awarded Highly Competitive CIRM Grant To Advance Lead Program, JUV-161, To Treat Myotonic Dystrophy Type 1
February 2, 2022
 · 
2 min read
AWARDS
  • NextGen Badge - Brighspot Rework_NextGen - Class of 2024.jpg
JOBS